Surrozen

Surrozen, Inc. is a preclinical stage biotechnology company, which engages in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. It is also focused on developing tissue-specific antibodies designed to engage the body's existing biological repair mechanisms with potential application across multiple disease areas, including inflammatory bowel disease, hepatitis, eye diseases, hearing loss, lung and airway diseases, and certain neurological disorders. The company was founded on August 12, 2015 and is headquartered in South San Francisco, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Surrozen, Inc. is a clinical stage biotechnology company. It engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.

Adamis Pharmaceuticals

VEON

Use these tips for diversifying your investments in penny stocks The post How to Diversify Your Penny Stock Investments  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Diversify Your Penny Stock Investments

Agora

Sobr Safe Inc

Spruce Biosciences

High volume penny stocks to watch right now. The post Penny Stocks To Buy?

Penny Stocks To Buy? 4 Cheap Stocks To Watch Right Now

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, will present on January 12, 2023 at 7:30 a.m. Pacific time at the 41st Annual J.P. Morgan Healthcare Conference.

Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference

Surrozen, Inc. (SRZN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Surrozen, Inc. (SRZN) Upgraded to Buy: Here's What You Should Know

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today reported financial results for the third quarter of 2022 and provided a corporate update.

Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced the presentation of data supporting the continued development of its lead therapeutic programs at United European Gastroenterology Week (UEGW), being held Oct. 8-11 in Vienna.

Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN) announced today that it has entered into a collaboration and license agreement with Boehringer Ingelheim to research and develop SZN-413 for the treatment of retinal diseases.

Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Surrozen , Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, announced today the publication of an article by Surrozen scientists in the journal Translational Vision Science and Technology The results observed with Surrozen's proprietary FZD4-specific agonist, SZN-413, highlight the potential for this novel mechanism of action to simultaneously address the retinal non-perfusion and vascular leakage observed in both oxygen-induced and VEGF-induced preclinical diabetic retinopathy (DR) models.

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today reported financial results for the second quarter of 2022 and provided a corporate update.

Surrozen Reports Second Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a clinical-stage company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that the first subject has been dosed in its two-part Phase 1 clinical trial for SZN-043 which is in development for the potential treatment of severe alcoholic hepatitis.

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced the presentation of data supporting the continued development of its lead therapeutic programs at Digestive Disease Week (DDW) 2022 in San Diego.

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a clinical-stage company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that the first subject has been dosed in its three-part Phase 1 clinical trial to evaluate SZN-1326 for the potential treatment of moderate to severe ulcerative colitis. The trial initiation is approximately one quarter earlier than previously expected. Surrozen also recently announced the publication of an article by Surrozen scientists in the journal Cellular and Molecular Gastroenterology and Hepatology The results highlight the potential for this novel approach to treating inflammatory bowel disease.

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

Results highlight potential for novel approach to treating IBD with Wnt mimetic Results highlight potential for novel approach to treating IBD with Wnt mimetic

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise

On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043 in the Third Quarter of 2022 On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043 in the Third Quarter of 2022

Surrozen Reports First Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that Craig Parker, President and Chief Executive Officer, will present at the BofA Securities 2022 Healthcare Conference at 4 p.m. PT on Wednesday, May 11.

Surrozen to Present at the BofA Securities 2022 Healthcare Conference

Preclinical data suggest that SZN-413 can simultaneously address retinal non-perfusion and leakage in blood vessels in retinal vascular diseases Preclinical data suggest that SZN-413 can simultaneously address retinal non-perfusion and leakage in blood vessels in retinal vascular diseases

Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results

-Initiation of Phase 1 clinical trials of SZN-1326 and SZN-043 expected in third quarter 2022

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

Surrozen to provide a business update including discussion of pipeline advancements Surrozen to provide a business update including discussion of pipeline advancements

Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Product Candidates SZN-1326 and SZN-043 Advance Toward Initiation of Clinical Studies in 2022

Surrozen Reports Third Quarter 2021 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc., (NASDAQ: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Craig Parker, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference at 10:00 a.m. ET on Monday, November 22. Interested parties may access the live webcast via the Investors section of the Surrozen website at www.surrozen.com. A replay of the webcast will be archived on the website.

Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, announced today that data from its liver disease program, including preclinical studies of SZN-043 showing improved liver metabolic function, were presented during The Liver Meeting 2021, organized by the American Association for the Study of Liver Diseases (AASLD) and held November 12-15.

Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc., (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Craig Parker, Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference at 4:40 p.m. ET on Tuesday, November 16. Interested parties may access the live webcast via the Investors section of the Surrozen website at www.surrozen.com. A replay of the webcast will be archived on the website.

Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference

Puma Biotechnology

Cogint

Harpoon Therapeutics Inc

MarketWise

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Sizzling Buy-Rated Biotechs Highlight 5 Top Stocks Under $10

Surrozen Inc (NASDAQ: SRZN) announced that preclinical data from its inflammatory bowel disease (IBD) program, SZN-1326, were presented during the 2021 United European Gastroenterology Week. Related:   See Why Surrozen Stock Is Surging On Tuesday.

News for Surrozen Stock (SRZN)